Cargando…

Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide

BACKGROUND: Teriflunomide 14 mg significantly reduced brain volume loss (BVL) and confirmed disability worsening (CDW) compared with placebo in the TEMSO core study. OBJECTIVE: To investigate the relationship between BVL from Baseline to Year 2 in the TEMSO core study and long-term CDW (Year 7) in t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sprenger, Till, Kappos, Ludwig, Radue, Ernst-Wilhelm, Gaetano, Laura, Mueller-Lenke, Nicole, Wuerfel, Jens, Poole, Elizabeth M, Cavalier, Steven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493202/ https://www.ncbi.nlm.nih.gov/pubmed/31198103 http://dx.doi.org/10.1177/1352458519855722

Ejemplares similares

Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA
por: Radue, Ernst-Wilhelm, et al.
Publicado: (2017)

Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies
por: Sprenger, Till, et al.
Publicado: (2022)

White matter lesion location correlates with disability in relapsing multiple sclerosis
por: Gaetano, Laura, et al.
Publicado: (2020)

Regional Cerebellar Volume Loss Predicts Future Disability in Multiple Sclerosis Patients
por: Parmar, Katrin, et al.
Publicado: (2021)

A comparison of brain magnetic resonance imaging lesions in multiple sclerosis by race with reference to disability progression
por: Nakamura, Yuri, et al.
Publicado: (2018)

Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis
por: Radue, Ernst-Wilhelm, et al.
Publicado: (2015)

Cerebellar Abnormalities Contribute to Disability Including Cognitive Impairment in Multiple Sclerosis
por: Weier, Katrin, et al.
Publicado: (2014)

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015)

White matter lesion filling improves the accuracy of cortical thickness measurements in multiple sclerosis patients: a longitudinal study
por: Magon, Stefano, et al.
Publicado: (2014)

Subcortical brain segmentation of two dimensional T1-weighted data sets with FMRIB's Integrated Registration and Segmentation Tool (FIRST)
por: Amann, Michael, et al.
Publicado: (2014)

Central nervous system atrophy predicts future dynamics of disability progression in a real‐world multiple sclerosis cohort
por: Tsagkas, Charidimos, et al.
Publicado: (2021)

Longitudinal patterns of cortical thinning in multiple sclerosis
por: Tsagkas, Charidimos, et al.
Publicado: (2020)

Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015)

Longitudinal changes of deep gray matter shape in multiple sclerosis
por: Tsagkas, Charidimos, et al.
Publicado: (2022)

Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML
por: Fischer-Barnicol, Bettina, et al.
Publicado: (2020)

Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial
por: Kappos, Ludwig, et al.
Publicado: (2021)

Classification of multiple sclerosis based on patterns of CNS regional atrophy covariance
por: Tsagkas, Charidimos, et al.
Publicado: (2021)

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
por: Kappos, Ludwig, et al.
Publicado: (2015)

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2015)

Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS
por: Zivadinov, Robert, et al.
Publicado: (2020)

A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis
por: Freedman, MS, et al.
Publicado: (2015)

An update of teriflunomide for treatment of multiple sclerosis
por: Oh, Jiwon, et al.
Publicado: (2013)

The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies
por: Freedman, Mark S, et al.
Publicado: (2017)

Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis
por: Comi, Giancarlo, et al.
Publicado: (2020)

Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
por: Bar-Or, Amit, et al.
Publicado: (2014)

Role of oral teriflunomide in the management of multiple sclerosis
por: Tanasescu, Radu, et al.
Publicado: (2013)

Neuropathy in multiple sclerosis patients treated with teriflunomide
por: Kilic, Ahmet Kasim, et al.
Publicado: (2023)

Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS
por: Arnold, Douglas L, et al.
Publicado: (2022)

Real-World Observational Evaluation of Hair Thinning in Patients with Multiple Sclerosis Receiving Teriflunomide: Is It an Issue in Clinical Practice?
por: Hendin Travis, Lori, et al.
Publicado: (2018)

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis
por: Miller, Aaron E, et al.
Publicado: (2012)

Review of teriflunomide and its potential in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2009)

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
por: Chan, Andrew, et al.
Publicado: (2016)

COVID-19 in teriflunomide-treated patients with multiple sclerosis
por: Maghzi, Amir Hadi, et al.
Publicado: (2020)

Teriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis
por: Moreira Ferreira, Vanessa F., et al.
Publicado: (2020)

Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide
por: Tornatore, Carlo, et al.
Publicado: (2022)

Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial
por: Kappos, Ludwig, et al.
Publicado: (2015)

Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use
por: O’Connor, Paul W., et al.
Publicado: (2013)

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
por: Laplaud, David-Axel, et al.
Publicado: (2019)

A comparative assessment of myelin-sensitive measures in multiple sclerosis patients and healthy subjects
por: Rahmanzadeh, Reza, et al.
Publicado: (2022)

Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study
por: Miller, Aaron E., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_mb1u5dbmro6oc9gf9ckb83okqu